Express treatment of non-small cell lung cancer, potential "first-in-class" therapy demonstrates anti-cancer activity

Surface Oncology today announced its potential "first-in-class" antibody SRF388 as a monotherapy for patients
with non-small cell lung cancer (NSCLC).
Two patients with squamous NSCLC achieved a confirmed partial response, and one patient with NSCLC remained stable for more than a year
.
These patients have undergone upfront systemic treatment
.
Based on this positive result, Surface has begun a phase 2 clinical trial of SRF388 in combination with the anti-PD-1 antibody Keytruda (pembrolizumab), and expects to announce the results in the
first half of next year.

Lung cancer is one of the most common types of cancer and the leading cause of
cancer death.
In 2020 alone, more than 1.
7 million people
died of lung cancer worldwide.
The pathological classification of lung cancer can be roughly divided into two categories: NSCLC and small cell lung cancer (SCLC), of which NSCLC is the highest lung cancer type, accounting for about 80%-85% of
lung cancer cases.
Most patients with non-small cell lung cancer are diagnosed at an advanced stage
.

SRF388 is a fully humanized antibody developed by Surface to inhibit the immunosuppressive cytokine IL-27
.
IL-27 has been found in certain tumor types to cause an inhibitory immune microenvironment, leading to tumor resistance to immune checkpoint inhibitors
.
For example, the researchers found that the IL-27 receptor signaling pathway contributes to the progression of hepatocellular carcinoma in mice, where IL-27 can act as an immune checkpoint to inhibit the activation of natural killer cells (NK) and innate immune cells
.
SRF388 can inhibit IL-27, thereby increasing the activation of natural killer cells and innate immune cells, and slowing down the progression of
hepatocellular carcinoma.
SRF388 has been granted orphan drug designation and fast-track designation by the US FDA for the treatment of liver cancer, and has the potential to become the first antibody
targeting IL-27 for clinical use.

According to the clinical data released this time, the objective response rate (ORR) of this trial examining SRF388 as a monotherapy for NSCLC was 22% (2/9)
before the data deadline of August 24, 2022.
It contains an ORR
of 100% (2/2) in patients with squamous NSCLC.
In addition, one of the adenocarcinoma patients showed long-lasting disease stability for more than 56 weeks
.
All three patients had previously received multiple lines of chemotherapy and anti-PD-(L)1 drugs and had relapsed
.

"We are excited to see SRF388 active as a monotherapy for recurrent NSCLC, a highly unmet medical need worldwide," said Dr.
Rob Ross, CEO of Surface.
To examine the possibility
of SRF388 in combination with Keytruda as a 2- to 4-line therapy for patients with NSCLC.
”

WuXi AppTec provides integrated, end-to-end new drug R&D and manufacturing services to the global biopharmaceutical industry, covering chemical drug R&D and manufacturing, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and manufacturing
.
If you have related business needs, please click the picture below to fill in the specific information
.